ISB News

ISB Post Doc Gets Patent for Protein that Blocks HIV

MartinShelton
Martin Shelton

Martin Shelton, a post doc in the Lee Hood lab, just received his first patent. He shared the following explanation with his 10-year-old nephew who’s a burgeoning scientist/inventor/engineer.

“We made a small molecule called a peptide (which is a sciency word for a piece of a protein). This peptide blocks a function that is key to the spread of the Human Immunodeficiency Virus (HIV, the virus that causes AIDS) within a person by trapping the virus within the infected cell and preventing it from infecting surrounding cells. It knocks out a similar function in cancer that could hinder tumor growth and the spread of cancer from one part of the body to another. We think it could one day be used to help treat HIV/AIDS or cancer, but it still has a long way to go and would have to pass many, many more tests before it could be used as a medicine. But in the meantime, it’s a useful tool for studying certain aspects of these diseases.”

Congratulations, Martin!

20130502-184513.jpg

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.